Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.58 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | CNR2 | P34972 | 4/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6803123 | 0.85 | POLB (0.48) | CNR1POLB | |
| SCHEMBL6803118 | 0.85 | POLB (0.48) | CNR1POLB | |
| SCHEMBL13569363 | 0.83 | CNR1 (0.81) | CNR1TACR1CNR2NPSR1POLB | |
| SCHEMBL468138 | 0.82 | PTPRB (0.43) | CNR1TACR1POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL3923639 | 0.82 | PTPRB (0.60) | — | |
| SCHEMBL3923645 | 0.82 | PTPRB (0.60) | — | |
| SCHEMBL6923899 | 0.79 | CNR1 (0.69) | CNR1TACR1CNR2NPSR1POLB | |
| SCHEMBL3766090 | 0.78 | PTPN1 (0.56) | POLBHTTMEN1KMT2A | |
| SCHEMBL6919966 | 0.75 | CNR1 (0.72) | CNR1TACR1CNR2SMN1; SMN2HTT | |
| SCHEMBL11398975 | 0.74 | CNR1 (0.63) | CNR1CNR2SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004074238-A1 | PHENETHYLAMINO SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | claimed |
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | claimed |
| WO-2004074238-A1 | PHENETHYLAMINO SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167183-A1 | Phenethylamino sulfamic acids | PTPRM, PTPRS, PTPRE | CNR1 4398/4885TACR1 3242/4885CNR2 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.